There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lifestance Health Group (LFST – Research Report) and LifeMD (LFMD – Research Report) with bullish sentiments.
Lifestance Health Group (LFST)
In a report released today, Craig Hettenbach from Morgan Stanley reiterated a Buy rating on Lifestance Health Group, with a price target of $10.00. The company’s shares closed last Friday at $5.71.
Hettenbach has an average return of
According to TipRanks.com, Hettenbach is ranked #790 out of 8786 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Lifestance Health Group with a $8.92 average price target.
See today’s best-performing stocks on TipRanks >>
LifeMD (LFMD)
Craig-Hallum analyst Alex Fuhrman reiterated a Buy rating on LifeMD today and set a price target of $15.00. The company’s shares closed last Friday at $9.70.
According to TipRanks.com, Fuhrman is ranked 0 out of 5 stars with an average return of
LifeMD has an analyst consensus of Strong Buy, with a price target consensus of $12.60, a 24.8% upside from current levels. In a report issued on April 12, B.Riley Financial also reiterated a Buy rating on the stock with a $12.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LFST:
- LifeStance management to meet virtually with Morgan Stanley
- LifeStance to Host First Quarter 2024 Earnings Conference Call on May 9, 2024
- LifeStance named Top Pick in Healthcare Technology at Morgan Stanley
- Lifestance Health Group Welcomes Teresa DeLuca to Board
- LifeStance price target raised to $8 from $7 at Barclays
